Research Papers:

Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors

Xin Min Zhao, Jing Zhao, Kai Lin Xing, Si Sun, Zhi Guo Luo, Hui Jie Wang, Jia Lei Wang, Jian Hua Chang and Xiang Hua Wu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:70865-70873. https://doi.org/10.18632/oncotarget.20145

Metrics: PDF 1838 views  |   HTML 2491 views  |   ?  


Xin Min Zhao1,*, Jing Zhao2,*, Kai Lin Xing1,*, Si Sun1, Zhi Guo Luo1, Hui Jie Wang1, Jia Lei Wang1, Jian Hua Chang1 and Xiang Hua Wu1

1Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

2Department of Medical Oncology, Tongji University Affiliated Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Shanghai 200433, China

*These authors have contributed equally to this work

Correspondence to:

Xiang Hua Wu, email: [email protected]

Keywords: non-small cell lung cancer, chemotherapy, epidermal growth factor receptor, tyrosine kinase inhibitors, carcinoembryonic antigen

Received: October 13, 2016     Accepted: May 14, 2017     Published: August 10, 2017


Background: Despite the widespread use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in advanced or recurrent non-small cell lung cancer (NSCLC), no biomarkers for predicting the efficacy of EGFR-TKIs in patients with EGFR-sensitive mutations have yet been identified. The purpose of our study was to explore the effect of baseline serum tumor markers in stage IIIB/IV NSCLC patients treated with EGFR-TKIs.

Methods: One hundred and seventy-seven patients with stage IIIB/IV NSCLC who harbored EGFR-sensitive mutations and were treated with EGFR-TKIs were retrospectively reviewed. Their levels of CEA, CYFRA 21-1, NSE and CA199 were measured before treatment with EGFR-TKIs.

Results: The response rate for all patients was 54.8%, with a median progression-free survival of 6.6 months and overall survival of 14.8 months. In univariate analyses, patients with CEA levels below the cutoff point (10 ng/ml) had higher RR, better PFS, and better OS than those with CEA levels above 10 ng/mL (RR: 69.2% vs. 43.4%, p= 0.001; mPFS: 7.8 months vs. 5.3 months, p=0.029; mOS: 18.8 months vs. 11.8 months, p=0.000). The baseline serum CEA level was an independent factor for RR (odds ratio [OR] =0.322, p=0.001), PFS (hazard ratio [HR] =1.45, p=0.025), and OS (HR=2.133, p=0.000).

Conclusion: Our study suggests that baseline serum CEA levels may play a role in predicting the efficacy of EGFR-TKIs in stage IIIB/IV NSCLC patients with EGFR-sensitive mutations who are treated with EGFR-TKIs.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20145